Syngene International, a contract research, development, and manufacturing organisation (CRDMO), is set to enhance its capabilities with a new GMP bioconjugation suite at its commercial biologics facility (Unit 3) in Bengaluru.

The state-of-the-art facility will support end-to-end services for antibody-drug conjugates (ADCs), from discovery through to GMP manufacturing. Set to be operational this financial year, the OEB-5-rated suite will streamline ADC development by enabling monoclonal antibody (mAb) production and GMP bioconjugation at a single site. It will also support advanced conjugates and related modalities. With over a decade of ADC expertise and a proven track record in handling highpotency payloads and linkers,

Syngene plans to further develop commercial-scale capabilities while continuing to support clinical programs. The facility will also offer process development, analytical characterization, and scale-up services for both early- and late-stage programs.